All Activity

Looking for a fast and thrilling card game? Andar Bahar Real Cash brings the excitement of the classic Indian game directly to your fingertips. Every round is packed with suspense, and the real cash rewards make every win even more satisfying. The platform is easy to use, secure, and designed for both beginners and seasoned players. Quick deposits and withdrawals mean you can focus on the fun, not the waiting. With fair gameplay and smooth graphics, each session is immersive and addictive. Don’t wait—experience the thrill today at https://andarbaharrealcash.com/.

“Today marks a small step forward, but we are up against incredible odds.” By Zach Wendling, Nebraska Examiner Health care practitioners who want to recommend medical cannabis to Nebraska patients are one step closer to having legal protections for writing the recommendation in the face of some state leaders’ opposition. The Legislature voted 30-7 on Friday to advance Legislative Bill 933, from State Sen. John Cavanaugh of Omaha. It would protect medical providers from criminal, civil or disciplinary penalties “solely” for issuing a written recommendation or stating that in their professional judgment, the potential benefits of cannabis outweigh potential harms. “It would create a step forward and hope and an opportunity for these families who have worked so hard, who have waited so long and would like to be able to have that conversation with their doctors and then potentially get some relief,” Cavanaugh said during debate. Lawmakers clarified that the practitioner wouldn’t be protected from malpractice or professional negligence claims, such as for not evaluating a patient or following the appropriate standard of care. An amendment to that end from Cavanaugh passed 35-4, as did a similar amendment from the Legislature’s Health and Human Services Committee, in a separate 38-4 vote. State Sen. Brian Hardin of Gering, HHS Committee chair, opposed LB 933 in committee but said the added language was an “important clarification.” “Practitioners are protected for the recommendation itself but remain fully responsible for conducting a thorough and appropriate patient evaluation before making it,” Hardin said. “Malpractice or professional negligence” is defined in law as failure to use “ordinary and reasonable care, skill and knowledge ordinarily possessed and used under like circumstances by members of his profession engaged in a similar practice in his or in similar localities.” In the 2024 general election, 71 percent of voters legalized possession of up to 5 ounces of medical cannabis with a recommendation, and 67 percent of voters created the regulatory Nebraska Medical Cannabis Commission. Getting to 33 votes Similar provider protections were included in a bill offering a larger regulatory framework proposed in 2025, LB 677 from State Sen. Ben Hansen of Blair. The bill failed 23-22, short of 33 necessary votes to overcome a filibuster. Cavanaugh’s LB 933 also would need 33 votes to change laws passed by voters, as required under the Nebraska Constitution. There remains a path to get there, with 12 senators either absent from or sitting out Friday’s vote. One of them, State Sen. Rick Holdcroft of Bellevue, who was “present, not voting,” supported LB 677 10 months ago but did not vote to advance LB 933. He’s the lone LB 677 supporter in that boat. Holdcroft helped get LB 677 out of the General Affairs Committee as committee chair. He said his biggest concern last year was funding for the commission, which is being remedied this year through state budget adjustments in LB 1071 and a separate General Affairs bill, LB 1235. Holdcroft noted the Medical Cannabis Commission has just finished licensing four cultivators, who have indicated it might be eight months to a year before there is enough crop for manufacturing and later distribution. “To start giving immunity to doctors who are going to make recommendations for a product that we’re not even going to have for a year is, I think, a little bit premature,” Holdcroft said. Cavanaugh, Hansen and other advocates argue the protections are needed so an eventual state program can exist. To date, they say no in-state physician has issued a recommendation, in part over fear of retribution, such as from law enforcement. And without protections, supporters worry there will be no patients able to access commission-licensed facilities. Nebraska Attorney General Mike Hilgers (R) rallied law enforcement against Hansen’s LB 677 in 2025 and spoke against the health care practitioner language. His office did not formally oppose LB 933, nor did the Nebraska Department of Health and Human Services. ‘Preponderance of scientific evidence’ State Sen. Jared Storm of David City, who led opposition to LB 677 last year, introduced an amendment to Cavanaugh’s bill to require that the health care practitioner’s recommendation be “based upon a preponderance of the current scientific evidence.” Storm argued the “simple and straightforward addition” was rooted in the Hippocratic Oath to “do no harm.” “If you’re against this amendment, you’re for recreational marijuana,” Storm said. “If you are for my amendment, you’re looking at this as medicine.” Cavanaugh argued the opposite, that LB 933 would support advocates and not push them to instead rally for recreational marijuana due to delays of accessing medical marijuana. Hansen made a similar plea last year. “If you do not want a recreational program, we must make our medical program functional,” Cavanaugh said. Storm, Hansen and Cavanaugh alike said they aren’t aware of any doctors who have been sued for malpractice or negligence for recommending medical cannabis nationwide. ‘Moral hazard’ or ‘dangerous road’? State Sens. Tanya Storer of Whitman and Bob Andersen of Sarpy County argued as Storm did that the debate was around public safety rather than medical cannabis. Said Storer: “Immunity creates a moral hazard. When there are no consequences, there is less incentive to exercise caution.” Cavanaugh and Hansen worried about the long-term implications of Storm’s proposal, arguing that it “muddies the water.” Hansen said it “could come back and bite us in the butt” around certain medications, such as Ivermectin used during the COVID-19 pandemic. Cavanaugh said he had talked with the Nebraska Medical Association and the malpractice provider for the association, who Cavanaugh said told him that Storm’s amendment would “create more uncertainty.” Hansen, a former HHS Committee chair, said he did understand where Storm was coming from and knows Storm’s opinion around medical cannabis. Hansen said using a “preponderance of scientific evidence” would exclude upward of 38 percent of medications issued off-label. “I think we’re gonna go down a very dangerous road in the future about micromanaging how a medical professional can prescribe medication for the future,” Hansen said. ‘Bit of a fixer-upper’ State Sen. Carolyn Bosn of Lincoln, a former prosecutor, clarified with Cavanaugh that nothing in LB 933 would protect a professional’s license if they went against their professional judgment. She said the legal standard is based on someone’s education, training and experience. She supported the protections. Storm said one issue was the difference between a “recommendation” for medical cannabis cannabis and a “prescription.” He noted opioids, for instance, are tracked under the state’s Prescription Drug Monitoring Program. Hansen proposed using that system in LB 677. Hardin, who ultimately did not vote on the advancement of LB 933, said he supported Storm’s amendment. He said marijuana had been studied “since wagons were crossing within a mile of my house on the Oregon Trail,” and that with dozens of states legalizing marijuana, the question is how to do that in the “safest possible way.” “I think it’s a little bit of a fixer-upper, and I think we’re getting there,” Hardin said. Storm’s amendment failed 22-19. It’s possible he may try again in future debate, as five senators were not at the State Capitol on Friday, including Storer. ‘Small step forward’ Crista Eggers of Nebraskans for Medical Marijuana said she was encouraged by the advancement of LB 933 but that some of the debate, particularly around Storm’s amendment, shows continued opposition to a functioning state program. “Today marks a small step forward, but we are up against incredible odds as this bill looks to move on to select file and final reading,” Eggers said after the vote. “Nebraskans have had few wins in this over-decade-long fight,” she continued. “Today is one of them.” LB 933 faces up to two more rounds of debate before, with 33 votes, it could be sent to Nebraska Gov. Jim Pillen for his signature. Vote to advance Legislative Bill 933 related to medical cannabis Aye (30): John Arch, Carolyn Bosn, Eliot Bostar*, Tom Brandt*, John Cavanaugh*, Machaela Cavanaugh*, Stan Clouse*, Danielle Conrad*, Wendy DeBoer*, Barry DeKay, Myron Dorn*, George Dungan*, John Fredrickson*, Dunixi Guereca*, Ben Hansen*, Jana Hughes*, Megan Hunt*, Margo Juarez*, Terrell McKinney*, Fred Meyer, Glen Meyer*, Jason Prokop*, Dan Quick*, Jane Raybould*, Merv Riepe, Victor Rountree*, Rita Sanders, Ashlei Spivey, Brad von Gillern and Dave Wordekemper*. Nay (7): Bob Andersen, Rob Clements, Mike Jacobson, Kathleen Kauth, Loren Lippincott, Dave Murman and Jared Storm. Present, not voting (7): Christy Armendariz, Beau Ballard, Brian Hardin, Rick Holdcroft*, Teresa Ibach, Mike Moser and Tony Sorrentino. Excused, not voting (5): Rob Dover, Bob Hallstrom, Dan Lonowski, Tanya Storer and Paul Strommen. *Voted for a broader medical cannabis framework proposed in 2025 (Legislative Bill 677). This story was first published by Nebraska Examiner. The post Nebraska Legislature Approves Bill To Protect Doctors Who Recommend Medical Marijuana appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

“The bottom line is that this is only going to benefit the unregulated market…and unfortunately, that’s going to result in a lot of unnecessary arrests for voter approved behavior.” By Megan Henry, Ohio Capital Journal The changes made by Republican state lawmakers to Ohio’s voter-passed weed law have now taken effect, including new criminal charges, along with the state’s new intoxicating hemp ban—which includes THC and CBD beverages. Ohio Senate Bill 56 became law Friday after Ohioans for Cannabis Choice failed to get enough signatures to get a referendum on the November ballot for voters to block the law. “Customers that seek our products out are often those very same customers that deal with stress, sleep, pain and anxiety, and they’re not trying to get high,” said Joey Ellwood, a hemp farmer in Tuscarawas County. “They might have to turn to pharmaceuticals. They might have to drive across state lines. It’s really a big question mark. They might be forced into undue burden with the pain, stress, sleep, and anxiety.” He said 6,000 Ohio businesses will be affected by the new law. “That’s a lot of jobs,” Ellwood said. Mark Fashian was the president of hemp product wholesaler Midwest Analytical Solutions in Delaware, Ohio, but he is heading out of state. “I know I can’t sell it in Ohio anymore,” he said. “[Friday] morning, I’d be considered a felon. It’s just unheard of. I can’t believe our politicians actually thought this was a good idea.” He worked with more than 500 stores around Ohio that sell intoxicating hemp products. “All of them are calling me in a panic, and I’m telling them the same thing—If I were you, I would get every product off the shelf and out of the store,” Fashian said. A lawsuit was filed this week in the Franklin County Court of Common Pleas to block the law from taking effect. Cleveland-based Saucy Seltzer, California cannabis drink maker Uncle Arnie’s, Illinois hemp manufacturer Organic Pharma Techs, and federal hemp license holder Amy Ellwood filed the lawsuit against the state. The plaintiffs are asking for a temporary restraining order to pause the law from taking effect. “Without immediate relief, plaintiffs will go out of business in Ohio on March 19, 2026 and thus suffer irreparable harm,” according to the lawsuit. “If they don’t go out of business, they risk facing, at minimum, felony marijuana possession and trafficking prosecutions,” it says. On the federal level, Congress voted in November to ban products that contain 0.4 milligrams of total THC per container when they voted to reopen the government. Previously, the 2018 Farm Bill said hemp can be grown legally if it contains less than 0.3 percent THC. There is a one-year implementation delay for the federal hemp ban, but states can create their own regulatory framework before then. The Ohio Cannabis Coalition is glad the new law is taking effect. “S.B. 56 gives law enforcement clear authority to ensure that intoxicating THC products are no longer freely sold to children through thousands of locations in Ohio,” OHCANN Executive Director David Bowling said in a statement. “This law will prevent unregulated products from reaching children and strengthen public safety across Ohio.” THC beverages Ohio lawmakers had a THC-infused beverage provision in the bill that would have allowed five milligram THC beverages until the end of December, but Ohio Gov. Mike DeWine (R) line-item vetoed that provision when he signed the bill into law in December. “We don’t believe that the governor had the right to line-item veto, essentially, he fundamentally changed the bill outside of things that had to do with appropriations,” said Bobby Slattery, founder of Fifty West Brewing Company in Cincinnati. Fifty West Brewing Company, Urban Artifact, Washington-based Cycling Frog, and Sarene Craft Beer Distributors filed a lawsuit earlier this month in the Ohio Supreme Court challenging DeWine’s line-item veto of the THC beverage provisions. “This is not the end [of THC beverages in Ohio],” Slattery. “I think that for the people of Ohio, this product is a needed product.” Fifty West Brewing produces Sunflower THC Seltzer and customers have been purchasing mass quantities of it this week before the ban, Slattery said. “There’s a lot of people in a panic right now,” he said. “They’re confused as to where they’re supposed to go if the beverages are taken away.” Fifty West Brewing made about $1.5 million in sales of Sunflower THC last year and was on pace to make about $3 million in sales from it this year, Slattery said. “This year we were at a point where we thought that we might be producing more THC beverage than we do beer,” he said. Slattery said some of his customers might opt for a THC beverage if they are trying to cut back on alcohol. “What we saw with Sunflower was it was this space in between a non-alcoholic beverage and an alcoholic beverage, sort of like a middle ground,” Slattery said. Marijuana law Ohio’s new law will change Ohio’s marijuana law, through which Ohioans voted to legalize marijuana in 2023. Recreational sales started in August 2024, and sales totaled more than $836 million in 2025. THC levels in adult-use marijuana extracts will be reduced from a maximum of 90 percent down to a maximum of 70 percent, cap THC levels in adult-use flower to 35 percent, and prohibit smoking in most public places. It will prohibit possessing marijuana in anything outside of its original packaging and criminalizes bringing legal marijuana from another state back to Ohio. The legislation also requires drivers to store marijuana in the trunk of their car while driving. “The bottom line is that this is only going to benefit the unregulated market,” said Morgan Fox, political director at the advocacy group National Organization for the Reform of Marijuana Laws, or NORML. “As people are being pushed into the unregulated market that is just adding insult to injury to them because they have less access to lab tested and quality controlled products, and whether because of financial reasons or because of simple lack of access that’s going to potentially put consumers in danger,” he said. The law will re-criminalize marijuana, he said. “I think that most people will not be aware of it, and unfortunately, that’s going to result in a lot of unnecessary arrests for voter approved behavior,” Fox said. This story was first published by Ohio Capital Journal. The post New Ohio Restrictions On Marijuana And Hemp THC Products Take Effect After Referendum Push Fails appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

In today’s lifestyle, people value convenience along with quality, and choosing call girls service in Pune ensures a refined experience where everything feels organized, discreet, and comfortable. A well-balanced experience is often defined by comfort and privacy, and many prefer Pune call girl options that offer a smooth and enjoyable atmosphere without unnecessary complications. Pune Call Girl || Call Girl in Pune || Pune Call Girl Service

An Idaho campaign says it’s collected enough signatures for a medical cannabis legalization initiative to exceed the statewide threshold for ballot qualification. But because it’s unclear how many are valid and whether activists have met a separate requirement for regional distribution of petitions, the Natural Medicine Alliance of Idaho (NMAI) is continuing to hold signature gathering events across the state to widen their coalition of supporters in the run-up to the May 1 submission deadline. As of Friday, NMAI has collected more than 73,000 signatures total—exceeding the 70,725 statewide requirement for valid petitions—according to the campaign’s website. To be certified for the ballot, the team also needs to submit signatures from 6 percent of registered voters from at least 18 of the state’s 35 legislative districts. Marijuana Moment reached out to NMAI for a status update about their progress to that end, but a representative was not immediately available. Meanwhile, teams of paid and volunteer petitioners are being deployed throughout the state to target high-traffic areas to gather signatures, and NMAI’s website features a map showing where registered voters can go to sign. The Idaho Medical Cannabis Act, which NMAI unveiled last October, would provide patients with qualifying conditions access to marijuana from a limited number of dispensaries and provide a regulatory framework for the market. Here are the main provisions of the Idaho Medical Cannabis Act: Health practitioners would be able to recommend medical cannabis to patients with conditions that include, but are not limited to, cancer, anxiety and acute pain. Medical marijuana patients or their designated caregiver could purchase up to 113 grams of smokeable cannabis, or 20 grams of THC extract for vaping, per month. The state would be start by issuing three vertically integrated cannabis business licenses, after which point it could license up to six total. Marijuana would be reclassified under state law as a Schedule II, rather than Schedule I, controlled substance. State and local law enforcement would be barred from assisting in federal drug enforcement activities related to the state-legal cannabis program. There would be anti-discrimination protections for those who use or sell marijuana in compliance from state law, preventing adverse actions by employers, landlords and educational institutions. It does not appear that there would be any equity-centered reforms, nor would the initiative provide for a home grow option. “We believe Idahoans deserve access to legal, compassionate, natural care right here at home,” NMAI’s website says. “Our mission is to give patients a legal pathway to natural medicine that can ease suffering and restore dignity without the fear of addiction.” “The Idaho Medical Cannabis Act is our first step forward. It creates a safe, tightly regulated medical program that allows qualified Idahoans to seek medical cannabis treatment with a valid diagnosis from a healthcare provider,” it says. “It supports Idaho agriculture, generates tax revenue to reinvest locally, and ensures that patients can find natural relief.” The campaign last month also released the results of a statewide poll showing that 83 percent of likely voters back medical cannabis legalization, including 74 percent of Republicans, 95 percent of Democrats and 92 percent of independents. Asked how they would vote if the current medical cannabis legalization does appear on the November ballot, 76 percent of respondents said “yes.” Of that cohort, 50 percent said they would “definitively” vote yes, and just 21 percent said they’d vote “no.” After the medical cannabis initiative was unveiled last year, a separate campaign that launched in 2024, Kind Idaho, told supporters that it would be suspending its own signature gathering for a ballot initiative to legalize the personal possession and cultivation of marijuana by adults. Kind Idaho previously introduced medical marijuana ballot measures intended to go before voters in both the 2022 and 2024 elections, but the efforts proved unsuccessful. Meanwhile, voters this year will see a different kind of proposal on the ballot: A constitutional amendment that the legislature approved to make it so only lawmakers could legalize marijuana or other controlled substances. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Legislators separately held a hearing last March to discuss a bill to enact medical cannabis legalization legislatively, but there hasn’t been meaningful action on the issue in the months since. Separately, a bill from Rep. Bruce Skaug (R) last year would have set a $420 mandatory minimum fine for cannabis possession, removing judges’ discretion to apply lower penalties. Skaug said the bill, which ultimately stalled in committee, would send the message that Idaho is tough on marijuana. House lawmakers also passed a bill to ban marijuana advertisements, though the Senate later defeated the measure. The post Idaho Medical Marijuana Initiative Exceeds Statewide Signature Count To Make November Ballot, Campaign Reports appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Campo East Africa Safaris is a premier East African safari outfitter for international travelers and tour agents. Our directors and consultants have many years of experience designing and operating East African safaris to destinations such as Maasai Mara, Ol Pejeta, Nairobi National Park, Amboseli, Lake Nakuru, Naivasha, Tsavo, Beach safaris and much more.

The WNBA seems positioned to join the ranks of sports leagues that have revised their marijuana policies, with details about negotiations for a collective bargaining agreement (CBA)—which has now reportedly been agreed to in principle—indicating that the women’s basketball league is moving to eliminate cannabis testing for players. As part of the negotiations between the Women’s National Basketball Players’ Association and WNBA, the league has reportedly put forward a number of potential policy changes, with proposals that touch on everything from salary caps to revenue sharing to travel expenses to drug testing rules. ESPN’s Ramona Shelburne posted screenshots of slides which were reportedly presented to players during a meeting with league representatives last month. In one slide titled “WNBA CBA Proposal: Summary of CBA Improvements,” a list of 37 potential compromises includes an item that says simply, “Elimination of Marijuana Testing.” Current WNBA policy treats cannabis significantly more restrictively compared to the NBA—and multiple other professional sports leagues beyond basketball that have also adopted reforms amid the state legalization movement. Marijuana remains listed as a “prohibited substance” for WNBA players, who are still tested for THC metabolites. First-time offenses generally result in treatment referrals, but repeated violations can lead to fines and suspensions. After last month’s WNBA CBA presentation, the players association came back with a counterproposal that included certain concessions around issues such as revenue sharing and housing, ESPN reported, but the latest version of the deal that was agreed to in principle this week hasn’t yet been released so it’s unclear what it specifically proposes as far as marijuana testing rules are concerned. Adding to @alexaphilippou recap from yesterday, ESPN has obtained some of the information that was was presented to players at yesterday’s meeting—summarizing the WNBA’s current positions https://t.co/imM5elSO6H pic.twitter.com/T9p2XRP42n — Ramona Shelburne (@ramonashelburne) February 3, 2026 The league did give some indication about its willingness to accept the changing tides around cannabis in 2024, when the WNBA team New York Liberty entered into a partnership with a CBD beverage company. But CBD, a non-intoxicating cannabinoid, is federally legal—and the sponsorship arrangement didn’t change the fact that players would still be tested and potentially penalized for testing positive for THC. Meanwhile, Brittney Griner—a WNBA player who was previously incarcerated in Russia over possession of marijuana—pulled out of an appearance at a cannabis event last year after discovering what she felt was a threatening message in her hotel room. Conference attendees had hoped to hear from Griner about the nature of her incarceration in Russia, which helped fuel international debate about cannabis prohibition laws domestically and abroad. How other sports leagues have navigated marijuana policy for players amid the reform movement. NBA, for its part, removed marijuana from the banned substances list for players in 2023, and it also freed them up to invest in and promote cannabis companies. The NFL, meanwhile, reached an agreement with its players union in 2024 to further reform its marijuana policies, significantly reducing fines for positive tests while increasing the allowable THC threshold for players. About four years after NFL ended the practice of suspending players over cannabis or other drugs as part of a collective bargaining agreement, the league again revised its Substances of Abuse Policy and Performance Enhancing Substances Policy. The National Collegiate Athletic Association (NCAA) in 2024 voted to remove marijuana from its banned substances list for Division I players. The reform builds on a 2022 change that increased the allowable THC threshold for college athletes, aligning NCAA’s rules with those of the World Anti-Doping Agency (WADA). In October, Nevada regulators officially adopted a rule change that will protect athletes from being penalized for using or possessing marijuana in compliance with state law. The head of the U.S. Anti-Doping Agency (USADA) blasted the “unfair” ban on marijuana for athletes competing in international sport events, including the Olympics that were underway in Paris at the time of the comments. USADA CEO Travis Tygart said it was “disappointing” that WADA has maintained the cannabis prohibition based on what he considers a misguided justification. WADA did carry out a review into its marijuana policy at the request of USADA and the White House Office of National Drug Control Policy (ONDCP) following the controversial suspension of U.S. runner Sha’Carri Richardson, who was barred from participating in the Olympics in 2021 after she tested positive for THC. Richardson said she used cannabis to cope with the recent passing of her mother. While UFC announced in late 2023 that it was formally removing marijuana from its modified banned substances list for athletes, the league notified participants that the reform didn’t apply under California State Athletic Commission (CSAC) rules. UFC advised fighters that they could be subject to a $100 fine by CSAS if they tested over 150 nanograms of THC per milliliter ahead of the UFC 298 event that took place in February. The New York-based clubs are partnering with Mynd Drinks, a hemp-based CBD sparkling beverage company that also made history in 2024 when it became an official partner of the Major League Baseball (MLB) team the Chicago Cubs. That year, NFL announced it was partnering with Canadian researchers on a clinical trial to test the safety and efficacy of CBD for pain management and neuroprotection from concussions—key issues for many football players who experience injuries as part of the game. Separately, NFL and the Denver Broncos in 2024 asked a federal court to reject a player’s lawsuit alleging discrimination over penalties he incurred due to positive THC tests from his prescribed use of a synthetic cannabinoid. In a joint motion to dismiss filed with the U.S. District Court for the District of Colorado, the league and team defended their marijuana policy for players, affirming it’s their view that use of cannabis can lead to on-field injuries, poor job performance and “alienation of the fans.” Photo courtesy of Chris Wallis // Side Pocket Images. The post WNBA Offers To End Marijuana Testing For Women’s Basketball Players As Part Of Reported Deal With Union appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

The Republican governor of Indiana says the fact that four neighboring states have moved to legalize marijuana in some form means Hoosiers are “probably going to have to address” the issue, while also likening cannabis reform to sports betting. Lawmakers in the state have already signaled that marijuana legalization isn’t in the cards in the 2026 session, meaning another year where Indiana will be an outlier as one of the few remaining states without effective medical or adult-use cannabis laws. But Gov. Mike Braun (R) said regional policy developments can’t be ignored. “I’m kind of agnostic on that issue,” he said on Thursday during a fireside chat focused on broadband access, “but when you’ve got four states surrounding you, you’re probably going to have to address it.” Braun was referring to the fact that three of Indiana’s bordering states—Illinois, Michigan and Ohio—have moved to legalize adult-use marijuana, while the fourth, Kentucky, has been implementing a medical cannabis program. “I think that kind of analog to all the different ways you can sports bet or bet in general, which has got a direct connection to high-speed internet—I’m going to be there listening and probably trying to measure out the pros and cons and make sure that we’re not the state that’s lagging most,” the governor said at a Fiber Broadband Association event in Indianapolis,, as State Affairs reported. To be sure, there have been some examples of lawmakers linking marijuana and sports betting, especially in the context of generating revenue by regulating and taxing the two markets. The tie-in to high-speed internet access, however, appeared to be an attempt to circle the conversation back to the main subject matter of the fireside chat. The governor said in January that he’s “amenable” to the idea of legalizing medical cannabis in the state, but GOP leadership in the legislature has balked at the prospect. Instead, Indiana legislators this session have been focused on efforts to ban hemp THC products—though it seems that fight is over for 2026 after a last-minute push failed late last month. Braun has also said that a move by President Donald Trump to federally reschedule marijuana could add “a little bit of fire” to the local push for cannabis legalization in his state. Months later, Trump did sign an executive order directing the attorney general to move cannabis from Schedule I to Schedule III of the Controlled Substances Act (CSA), but that hasn’t materialized yet. Among Indiana residents, however, a survey released in January found that nearly three in five back legalizing cannabis for medical and recreational use. Specifically, the annual Hoosier Survey from the Bowen Center at Ball State University (BSU) found that 59 percent of residents are in favor of legalizing cannabis for both medical and recreational purposes. An additional 25 percent back only allowing patients to access medical marijuana, raising the total support for that reform to 84 percent. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Braun, for his part, previously said that “it’s probably time” to allow access to therapeutic cannabis among patients in the state. Those comments came alongside a separate poll indicating that nearly 9 in 10 Indiana adults (87 percent) support marijuana legalization. Top Republicans in the legislature, however, have openly opposed marijuana reform. “It’s no secret that I am not for this,” Senate President Pro Tem Rodric Bray (R) said in late 2024. “I don’t have people coming to me with really compelling medical cases as to why it’s so beneficial. And any state that I’ve seen pass medical marijuana is essentially passing recreational marijuana.” House Speaker Todd Huston (R) doubted any medical benefits associated with marijuana, calling the substance “a deterrent to mental health.” He and others suggested that lawmakers supportive of the reform merely want to boost state revenue. A number of marijuana reform bills were introduced for the Indiana legislature’s 2025 session, including one—from Reps. Jim Lucas (R) and Shane Lindauer (R)—that would have legalized medical marijuana for people with “serious medical conditions as determined by their physician.” Photo courtesy of Brian Shamblen. The post Indiana Will ‘Have To Address’ Marijuana Legalization Because It’s ‘Lagging’ Behind Neighboring States, Governor Says appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

We remain a favorite as our Delhi call girls service with its sophisticated Call Girls Number who add warmth and personality. Clients also can find beautiful call girls in Delhi by our well-organized Delhi call girls service.

Massachusetts lawmakers have approved a pair of psychedelics bills that would create pilot programs allowing eligible patients to access novel treatments such as psilocybin, with the intent to gather information to inform best clinical practices and prepare for potential broader, regulated availability. Members of the Joint Committee on Mental Health, Substance Use and Recovery passed the legislation—H.2203 and H.4200 from Reps. Marjorie Decker (D) and James O’Day (D), respectively—on Wednesday. Both measures advanced in 9-3 votes. Decker’s bill focuses on psilocybin therapy, requiring the Department of Public Health (DPH) to establish a pilot program where patients 21 and older with post-traumatic stress disorder (PTSD), depression and end-of-life anxiety could receive the psychedelic in a clinical setting at authorized mental health, hospice, veterans administration and other community services facilities. University researchers would also be involved, tasked with supervising and analyzing the results of the innovative treatment initiative that would follow regulatory pathways approved by the federal Food and Drug Administration (FDA). Only psilocybin could be administered under the program—unlike the separate bill from O’Day that would broadly permit treatment with “psychedelic materials” defined by DPH—but its scale and intent are more expansive in other ways. Specifically, DHS would be required to “establish professional standards for regulated psychedelic use and criteria for participation in the pilot, including the number of universities that may participate in the pilot,” and “preference shall be given to universities within the Commonwealth’s public university system.” “The department shall develop local training and certification frameworks for psilocybin facilitators to sustain capacity beyond the pilot’s conclusion,” the bill text says, adding that local pilots “shall collect and provide data relevant to potential coverage for the cost of psilocybin-assisted therapy, as determined by the department.” Within one year of the effective date of the law, which requires the pilot program to operate for at least two years, DHS would need to submit a a peer-reviewed report to the legislature that includes “a study of the statewide efficacy of the pilot, including local community impacts and the feasibility of coverage for psilocybin-assisted therapy under MassHealth, consistent with any applicable federal guidelines.” The bill from O’Day, meanwhile, would also create a psychedelics pilot program in the Commonwealth—but it would be designed to prioritize data collection on best practices in the clinical administration of psychedelic-assisted therapy. Under the legislation, only three clinics could receive permits from DPH to administer “psychedelic materials,” as defined by the department, to patients with depression, anxiety, PTSD, substance use disorder (SUD) and other “clinically appropriate” conditions. A multi-disciplinary team, overseen by a licensed physician, would be involved in the psychedelic pilot at each of the clinics, which would need DPS approval to operate “for the purposes of collecting patient outcomes data regarding the benefits of psychedelic pharmacotherapy.” “Eligible pilot program organizations must exclusively focus operations and treatment on mental health,” the bill says. And it notably contains provisions stipulating that the pilots “cannot be subsidiaries, affiliates or members of cannabis industry organizations, psychedelic molecule development companies or pharmaceutical companies.” “All pilot program participant organizations must track patient care outcomes data related to the identification, diagnosis and psychedelic treatment of depression, anxiety, post-traumatic stress disorder and substance use disorder. These data sets must be shared with the department to assist in the refinement of best clinical protocols and final regulatory frameworks for the safe use of psychedelic material in Massachusetts.” O’Day said ahead of the joint committee vote that, “as someone in long-term recovery, it’s my opinion that any move towards the use of psychedelics in Massachusetts should focus exclusively on mental health and SUD treatment.” He also stressed that “it’s important the regulation should be free from the influence of the cannabis and pharmaceutical industries.” Mass Healing, a non-profit focused on psychedelic policy and education that’s backing both reform measures, celebrated their committee passage on Thursday. The organization helped coordinated with impacted individuals—including an Army veteran and Harvard University researcher, Rita Graham—to testify in support of the proposals in committee. “I sit before you as a veteran and one of the first women to serve in combat arms positions. I’m also a former social worker and now a policy advocate working at the intersection of trauma and healing,” Graham said. “I’ve spent years as a researcher and a survivor of sexual violence, which is one of the most pervasive, yet ignored wounds of military service.” “Healing veterans heals communities, and Massachusetts has the opportunity to lead that change,” she said. Wednesday’s votes come months after members of the state legislature’s Joint Committee on Public Health approved separate psychedelics reform measures, including one to create a regulatory framework for psilocybin and another that would legalize the use of the psychedelic by veterans, law enforcement and first responders. A Senate bill to create a psilocybin therapy pilot program, sponsored by Sen. Cindy Friedman (D), also advanced through the committee process last year. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — While multiple cities across Massachusetts have enacted local psychedelics decriminalization initiatives, voters rejected a statewide ballot measure last year that would have legalized substances such as psilocybin, ibogaine and DMT for adults. Ahead of that vote, the governor signed a military veterans-focused bill that includes provisions to create a psychedelics working group to study and make recommendations about the potential therapeutic benefits of substances like psilocybin and MDMA. Meanwhile, the legislature’s Joint Committee on the Judiciary last July held a hearing on four of 12 psychedelics-related bills that were filed for in the 2025 session, with the Massachusetts Psychiatric Society (MPS) endorsing one that would decriminalize certain entheogenic substances. Photo courtesy of Dick Culbert. The post Massachusetts Lawmakers Approve Bills To Create Psychedelic Therapy Pilot Programs appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

The evening became more pleasant when I chose a reliable option through Raipur Escorts Service, where everything was managed professionally and made the time truly worthwhile.

The Delhi escorts exude a soft and seductive calm that is immediately alluring. It is a comfort that is full of underlying tension. The Russian Escorts in Delhi understand how to cultivate intimacy through conversation and smiles. The soft charm is very enticing. It is genuine, relaxed, and very tempting.

New York senators have approved a bill related to reciprocity for out-of-state medical marijuana patients and the availability of pre-rolled joints in the medical cannabis market—even though the state has already enacted those reforms separately. The Senate Health Committee on Tuesday passed the legislation from Sen. Jeremy Cooney (D) in a 9-3 vote, advancing it to the floor for consideration, where on Thursday it advanced to third reading. Under the proposal, a “person who is not a resident of this state, but who is authorized to engage in the medical use of cannabis under the laws of such person’s state or jurisdiction of residence, is deemed to hold a valid registry identification if the person provides legitimate documentation and abides by the legal limits on the possession, delivery and production of cannabis for medical purposes in this state.” The legislation directs the Cannabis Control Board (CCB) to establish regulations, and it would also be authorized to “enter into reciprocity agreements with other states with medical cannabis programs.” Further, the measure, S3105, tasks the board with promulgating rules for the “approval of pre-roll products in the medical cannabis program”—though those products are also already legal for patients to purchase under state law. If passed by the legislature and signed into law by the governor, the reforms would take effect immediately. Tuesday wasn’t the first time the Health Committee took up the bill. Last year, in the first half of the two-year legislative session, the measure moved through that panel and passed on the Senate floor before stalling out in the Assembly. Now the measure has cleared the panel again. But the rationale behind advancing the measure is somewhat unclear, as the governor last year signed separate legislation from Cooney into law that contained provisions that are in effect granting reciprocity to out-of-state medical cannabis patients. Also, patients are already able to buy marijuana pre-rolls, among other product types, under existing rules. A spokesperson for the senator’s office told Marijuana Moment on Wednesday that the legislation enacted in November “was a little more big picture about the evolution of the program,” whereas the bill that moved through committee “is a little more targeted in its scope.” However, the staffer said they were awaiting further clarification from Cooney’s legislative team. In addition to the reciprocity provisions, the already-enacted law streamlines the patient certification process and allows adults 18 and older to grow their own cannabis plants for therapeutic use. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Meanwhile, last month the senator separately introduced legislation that would allow New York liquor and wine stores to obtain a permit to sell low-dose cannabis-infused drinks at their businesses. Also, the governor of New York last month signed legislation into law that revises zoning requirements for licensed marijuana businesses, granting more flexibility to retailers located within certain distances of schools and places of worship. In January, New York officials released a set of reports providing a 2025 end-of-year status update on the evolution of the state’s medical and adult-use marijuana markets—touting record sales, revenue hauls for state coffers, licensing approvals, equity initiatives and more. All told, retail cannabis sales in New York have exceeded $2.5 billion since the passage of recreational legalization, including $1.6 billion that was generated last year alone as of November. Also, licensed storefronts nearly doubled from 261 in 2024 to 556 in 2025. Last July, meanwhile, New York officials announced the first round of grants under a $5 million program to help retail marijuana businesses owned by justice-involved people cover startup costs. The post New York Senators Approve Bill Addressing Medical Marijuana Reciprocity For Out-Of-State Patients And Pre-Rolled Joints appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Pretty good post. I just stumbled upon your blog and wanted to say that I have really enjoyed reading your blog posts. Any way I'll be subscribing to your feed and I hope you post again soon. Big thanks for the useful info. daftar alexistogel

THC in Medicare CBD coverage plan; Marijuana bills on VA gov’s desk; IA psilocybin; Study: Cannabis safer than alcohol & tobacco Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… Before you dig into today’s cannabis news, I wanted you to know you can keep this resource free and published daily by subscribing to Marijuana Moment on Patreon. We’re a small independent publication diving deep into the cannabis world and rely on readers like you to keep going. Join us at https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW The Centers for Medicare & Medicaid Services will reportedly allow up to 3 milligrams of THC in CBD products being covered under a forthcoming insurance pilot program—which could conflict with a law recently signed by President Donald Trump to recriminalize hemp products containing more than 0.4 milligrams of THC per container. Reps. Guy Reschenthaler (R-PA) and Troy Carter (D-LA) filed a bipartisan bill that would let state-legal marijuana businesses list on stock exchanges like Nasdaq and NYSE—and more broadly shield companies from being punished for providing financial, accounting, insurance, advertising or other services to the cannabis industry. Virginia Gov. Abigail Spanberger (D) has until April 13 to decide whether to sign, veto or propose amendments to several marijuana bills—including ones to legalize recreational sales, resentence past convictions, protect consumers’ parental rights and allow medical cannabis in hospitals. The Iowa Senate Health and Human Services Committee approved a House-passed bill to create a psilocybin therapy program for people with PTSD, with amendments. A new government-funded study concludes that alcohol and tobacco are more harmful to users and to society than marijuana is—and that the biggest harm associated with cannabis is “organized criminal activity” in the illegal market. “Alcohol causes the most harm overall…followed by tobacco, nonprescription opioids (like fentanyl), cocaine, methamphetamine, and cannabis.” / FEDERAL The U.S. Army is punishing a reserve officer over his ownership of a state-licensed marijuana business in New York. The Drug Enforcement Administration filed technical amendments to a rule concerning changes to the order form for Schedule I and II controlled substances. Sens. Pete Ricketts (R-NE) and Richard Blumenthal (D-CT) led a letter urging the Food and Drug Administration to schedule kratom and 7-OH. / STATES Nevada Gov. Joe Lombardo (D) appointed the executive director of the Cannabis Compliance Board as the new director of the Governor’s Office of Energy. Mississippi lawmakers sent Gov. Tate Reeves (R) bills to expand medical cannabis access and to support clinical trials on ibogaine. The Connecticut legislature’s General Law Committee approved a bill to increase THC potency limits in cannabis products. A Georgia representative filed a resolution urging that the state reschedule marijuana. A New York court ruled that state marijuana regulations are not preempted by federal law. A federal judge rejected Oregon regulators’ motion for a favorable judgement in a lawsuit challenging the state’s restrictions on psilocybin services access for homebound patients. Arizona regulators announced a recall of marijuana products due to possible contamination with aspergillus. Oklahoma regulators announced a recall of medical cannabis products over testing inaccuracies. Massachusetts regulators held a hearing on a proposal to freeze marijuana cultivation licenses. Michigan regulators published guidance on the state’s new marijuana wholesale tax. Nevada Cannabis Advisory Commission subcommittees will meet on Tuesday. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — / INTERNATIONAL Isle of Man officials awarded the territory’s first medical cannabis business license. / SCIENCE & HEALTH A study found that “breath is an alternative, non-invasive sample matrix that holds promise for identifying recent cannabis use.” A study found that “the regular cannabis use group showed no significant impairment in driving performance 12-15 hours after last cannabis use the night before, compared to the control group.” / ADVOCACY, OPINION & ANALYSIS Americans for Safe Access published a report on medical cannabis patients’ access to organ transplants. / BUSINESS Jushi Holdings Inc. and a former chief operations officer settled a lawsuit in which he claimed he was fired in retaliation for complying with safety standards. Michigan retailers sold $234.6 million worth of legal marijuana products in February. / CULTURE Rapper Afroman won a defamation lawsuit filed by Ohio police who sued him over music videos in which he used home security footage to mock their marijuana raid of his home. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: The post Cannabis biz could list on stock exchanges under new congressional bill (Newsletter: March 20, 2026) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Snow Rider 2 is an incredibly engaging, high-speed skiing game that challenges your reflexes with simple yet addictive gameplay.

I found that site very usefull and this survey is very cirious, I ' ve never seen a blog that demand a survey for this actions, very curious... toto togel

Pretty good post. I just stumbled upon your blog and wanted to say that I have really enjoyed reading your blog posts. Any way I'll be subscribing to your feed and I hope you post again soon. Big thanks for the useful info. bandar togel

Delhi escorts have a knack for building desire through anticipation. Their presence is both soothing and exhilarating. Russian Delhi Escorts give chemistry the time to develop on its own, so every second is full of possibility. It is inviting, warm, and unforgettable.

The Centers for Medicare & Medicaid Services (CMS) will soon be launching a pilot program that would cover the costs of CBD products for eligible patients under certain federal health insurance plans. But newly reported details about the effort signal that it policy could conflict with a separate law redefining hemp in a way that severely restricts allowable THC content. CMS Administrator Mehmet Oz has previously described the CBD coverage plan that’s being implemented in response to an executive order President Donald Trump signed in December that also directs the finalization of a federal marijuana rescheduling rule, saying the CBD components of the plan could be rolled out as early as April. But as the agency has prepared to provide cannabidiol coverage under the pilot program, it has set an initial limit of 3 milligrams of total THC (including delta-8, delta-9 and delta-10 THC, for example) per serving—as Cannabis Wire first reported—which is more than seven times the THC limit for hemp-derived cannabinoid products as defined under a spending bill Trump signed last year. The cannabis section of that agriculture-focused spending legislation restricts total THC content to .4 milligrams per container. And that law, which industry stakeholders say will effectively eliminate the consumable cannabinoid market, takes effect in November. A CMS spokesperson told Cannabis Wire that agency “will adjust its definition in accordance with the law,” without clarifying how it arrived at the 3 milligram total THC limit in the first place. Bipartisan lawmakers and hemp industry advocates have pushed to delay the enactment of the new hemp THC restrictions signed by Trump, but those efforts have not gained traction. An amendment on the issue was not adopted at a recent House committee markup of a new Farm Bill. Marijuana Moment reached out to CMS further inquiring about the apparent THC policy conflict, but a representative was not immediately available. The planned pilot program “expressly excludes inhalable products,” the spokesperson also said. And the “orally administered” CBD products that are made available would be subject to “state and local law,” though that raises other questions given the complex patchwork of state-level hemp and cannabinoid policies. In any case, the newly reported details about the yet-unpublished rules for the pilot program comes weeks after an executive at a hemp company that’s been collaborating with CMS said that the agency had already finalized its plans for federal health insurance coverage of cannabidiol. “This pilot will help the [Food and Drug Administration, or FDA] move from uncertainty into a practical framework with clear dosing, risk mitigation and clear manufacturing label expectations that end up rewarding the responsible companies and, in the end, protect and serve the consumer,” Jared Stanley, co-founder of the cannabis company Charlotte’s Web, said. “As far as the population, it was important to note that it was stated in the briefing that this is starting in a pilot, but expecting to expand beyond just the pilot,” he said. “So that’s multiple indications that we expect to see. And we’re very excited. It has amazing potential.” Relatedly, the CMS spokesperson told Cannabis Wire that while it couldn’t provide specific numbers around patients expected to participate in the pilot program, those details will come out when they’re available, and the agency would generally provide updates on the rollout “in the coming weeks.” Asked about the status of the CBD rulemaking last month, CMS directed Marijuana Moment to a webpage with an FAQ that describes the integration of hemp into a Beneficiary Engagement Incentive (BEI) program under the agency’s Long-term Enhanced ACO Design (LEAD) Model. “The Substance Access BEI gives model participants the option of consulting with their patients about the possible use of eligible hemp products,” the CMS page says. “The implementation of this BEI and any related dispensing would be funded entirely at the participant’s expense; CMS would not cover the cost of such products. Further, CMS will have strict program integrity safeguards to ensure that these incentives do not result in program or patient abuse.” “The Substance Access BEI is only available to participants in states where the eligible hemp products are considered legal,” it says. While the broader rules on the CBD Medicare pilot program haven’t been publicized yet, CMS’s website briefly details how it’s navigating hemp-related issues as part of regulatory models under LEAD, the Accountable Care Organization (ACO) and the Enhancing Oncology Model (EOM). Oz, the CMS administrator, explained in December that the policy change will “allow millions of Americans on Medicare to become eligible to receive CBD as early as April of next year—and at no charge if their doctors recommend them.” He added that Medicare Advantage insurers CMS has contacted are “also agreeing to consider CBD to be used for the 34 million Americans that they cover.” One outstanding question concerns coverage eligibility. As described by the administrator in December, it would affect those 65 and older who qualify for Medicare, but the specific qualifying conditions weren’t detailed. There were repeated mentions of chronic pain, specifically related to cancer, but it’s possible the CBD eligibility criteria includes additional conditions. At the signing ceremony, Oz also gave kudos to Howard Kessler, founder of The Commonwealth Project, which produced a video about the benefits of cannabidiol for seniors that Trump shared on Truth Social last year and who apparently has pressed the president to enact reform to expand cannabis access. While CMS implemented an earlier final rule last April specifically stipulating that marijuana, as well as CBD that can be derived from federally legal hemp, are ineligible for coverage under its Medicare Advantage program and other services, the agency is now revising that policy. CMS had already announced certain changes as part of a rulemaking process that was unveiled late last year, affecting “marketing and communications, drug coverage, enrollment processes, special needs plans, and other programmatic areas” for insurance programs it oversees. One of those changes dealt with cannabidiol coverage. The rule as proposed would amend regulations, which currently state that any “cannabis products” cannot be covered. The policy would prevent coverage for only “cannabis products that are illegal under applicable state or federal law, including the Federal Food, Drug, and Cosmetic Act.” Since hemp and its derivatives like CBD are federally legal, the change suggests patients in states where such products are legal could make valid insurance claims to pay for the alternative treatment option, as long as the product is also federally legal. Meanwhile, following the White House announcement in December, Oz spoke with NewsNation about the policy change, responding to a question about how the broader marijuana rescheduling decision squares with the Trump administration’s aggressive efforts to stymie the flow of other illicit drugs, particularly fentanyl. “We think they fit hand in hand,” he said. “This is really about researching—specifically CBD, which is hemp-derived endocannabinoids [sic]—are actually worthy of Americans using them,” he said. “It’s hard to do some of this work, especially with medical marijuana. And this is not about legalization of marijuana.” “There is no legalization language at all,” he added. “It’s about rescheduling this class of product so that it can be researched more readily.” The idea that marijuana has no medical value, as its currently defined as a Schedule I drug, is “just patently wrong for marijuana,” he said, noting that the Food and Drug Administration (FDA) has approved certain cannabis-based drugs for conditions such as epilepsy “that work quite nicely.” “That belief that it should be Schedule I is just an incorrect place to put it,” he said. “Schedule III seemed to make sense to the president. He argued that it allows us to do the research more readily.” “We’re finding a way to allow Medicare beneficiaries to get access to some of these products. And so, within Medicare, we have the ability, for the first time ever—and we delivered on this promise to the president today—to allow doctors to recommend hemp-derived CBD for patients who have cancer, for example, and have a lot of pain from that.” The administrator said surveys show a majority of seniors who take CBD for pain management find it beneficial, and the White House wants to “make it easier for patients to access this” and allow them to access the cannabinoid at “no charge” through the federal health insurance program. Meanwhile, Oz took a different tone last month when he warned that “there are going to be consequences” as more Americans choose marijuana over alcohol—including problems caused by “high-dose hemp and CBD.” In the background, the U.S. Department of Health and Human Services (HHS) and FDA recently submitted proposed regulations concerning CBD enforcement and compliance with the White House Office of Management and Budget’s (OMB) Office of Information and Regulatory Affairs (OIRA). There’s been speculation that the rule could be related to the CMS pilot program, but that hasn’t been confirmed. And it’s also possible the proposal is linked to an unrelated FDA mandate from Congress to produce a list of known cannabinoids ahead of the federal hemp redefinition. Photo courtesy of Kimzy Nanney. The post Federal CBD Health Insurance Plan Will Reportedly Allow THC Amount Far Exceeding Hemp Limit Signed By Trump appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

An Iowa Senate panel has approved a House-passed bill to create a state-regulated therapeutic psilocybin program for patients with post-traumatic stress disorder (PTSD). The Senate Health and Human Services Committee advance the legislation from Rep. John Wills (R) in a voice vote on Thursday. The panel adopted an amendment from Sen. Dennis Guth (R) to narrow the scope of the bill to allow only people with PTSD to access the psychedelic therapy instead of the broader version that was passed by the House last year. The revised measure also eliminates provisions that would have created a new Psilocybin Production Establishment Licensing Board under the Iowa Department of Health and Human Services (HHS) to oversee the industry. Instead, the current Medical Cannabidiol Advisory Board would take on the responsibility of regulating the psychedelic and be renamed to the Medical Controlled Substance Advisory and Licensing Board. “I have some friends, some people I know, that I think would really benefit from this,” Guth said. “But we have to be careful how we proceed with this.” Sen. Kara Warme (R), the chair of the panel, agreed, saying that the “bill is not done” and still needs some more work before it should be enacted into law. “I think we have an interesting challenge as lawmakers to look at a really promising potential solution to help Iowans with PTSD, especially our veterans, who are facing this—but also there is a lot of unknowns that remain,” she said. “It’s a new potential solution, and so I appreciate the work that’s going in to make sure that we do this in the right way that’s cost effective for tax taxpayers, and also thinks through the risks and rewards of something new and not heavily studied like this.” If enacted into law, HF 978 would allow patients with PTSD who receive recommendations from medical professionals to legally access psilocybin produced in-state by licensed entities. Administration sessions for the psychedelic would be supervised by registered facilitators who would need to complete state-specified psilocybin education. Administration sessions themselves would need to take place at registered clinical locations and would need to be video recorded. Those records would need to be available for inspection by state officials upon request. Local governments could not outright ban psilocybin facilities, nor could they deny them appropriate licenses based merely on the fact that the psychedelic is federally illegal. Notably, a licensed psilocybin production facility could be co-located with one of the state’s few licensed medical cannabis producers—known in Iowa as medical cannabidiol producers—and the bill says regulators may grant psilocybin licensing preferences to those existing cannabis producers. Facilities couldn’t be located within 1,000 feet of a community location or 500 feet of a residential area. Only people 21 and older and who do not have a misdemeanor for drug distribution or any felony on their record could work at psilocybin producers, and licensees themselves would face background checks. Up to four independent testing labs could be licensed under the bill, and the state could also establish its own lab. License applications would be accepted beginning July 1, 2026. The measure also directs HHS to conduct a study on “the use of psychedelic compounds other than psilocybin in the treatment of medical conditions.” — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — The bill as originally introduced would have limited the psilocybin therapy program only to patients with PTSD, with a ceiling of 5,000 participants at any one time, but those provisions were removed with a House floor amendment last year. Now, however, the Senate panel has added back in the limitation to PTSD patients only. Last year, Gov. Kim Reynolds (R) vetoed separate legislation that would have allowed doctors in the state to immediately prescribe a synthetic form of psilocybin in the event of federal approval of the psychedelic substance by the U.S. Food and Drug Administration (FDA), arguing that it “surrenders state authority to make an informed determination about classification to federal officials.” “This decision is not a dismissal of the emerging science or the sincere advocacy behind this legislation,” the governor said at the time. “Rather, it is a call for a more deliberate and Iowa-centric approach.” Image courtesy of CostaPPR. The post Iowa Senators Approve Psilocybin Therapy Bill For PTSD Patients appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Marijuana businesses would be able to list on national stock exchanges such as Nasdaq and the New York Stock Exchange (NYSE) under a bipartisan congressional bill filed on Wednesday that would also more broadly shield companies from being punished for providing financial, accounting, insurance, advertising or other services to the cannabis industry. Reps. Guy Reschenthaler (R-PA) and Troy Carter (D-LA) are again sponsoring the Capital Lending and Investment for Marijuana Businesses (CLIMB) Act—a piece of incremental cannabis reform that would resolve an issue that’s long frustrated stakeholders and comes as a federal marijuana rescheduling proposal remains pending. The legislation is substantively the same as earlier versions of the CLIMB Act filed in the 117th Congress, with certain technical formatting changes, according to a discussion draft obtained by Marijuana Moment. The final bill text has not yet been posted. A central function of the bill is to free up cannabis industry access to financial lending and investment opportunities, in part by providing protections for private financial institutions and government agencies that provide such services to traditional markets. Another notable section would provide safe harbor for national securities exchanges and market participants that “have listed, list, or intend to list,” “permit the trading of” or “facilitate the offering, listing, or trading” of such cannabis-related securities. In other words, cannabis businesses would be permitted to list on major stock exchanges, including Nasdaq and NYSE. That would represent a boon for the industry, legitimizing their presence on Wall Street even as marijuana remains federally illegal. Overall, the legislation stipulates that federal agencies “may not take any adverse action against a person solely because the person provides business assistance to a cannabis-related legitimate business or service provider.” The full list of activities that people and businesses could offer to the cannabis industry without being federally penalized includes: “providing a financial product or service; selling insurance or surety products; providing debt or equity capital or receiving dividends, interest, or distributions of that capital; providing accounting services; the sale, lease, or rental of real estate; providing equipment, parts, substances, or testing services needed to produce cannabis in compliance with the laws and regulations in the applicable State; providing advertising or marketing services; providing management consulting services; providing legal services or compliance services; providing information technology, software, or communications services; provision of packaging, transportation, or other logistics services; and underwriting, dealing, placement or public distribution of securities issued by a cannabis-related legitimate business, including the listing of any such securities on any exchange or trading venue, or any provision of services related to the foregoing.” This legislation takes a targeted approach to cannabis reform in the financial and regulatory sector, whereas another bipartisan bill that advocates and stakeholders have pushed for—the Secure and Fair Enforcement Regulation (SAFER) Banking Act—would more broadly safeguard financial institutions that work with marijuana businesses from being penalized by federal regulators. The SAFER Banking Act has not yet been refiled in the current 119th Congress, however. Stakeholders are also awaiting administrative action on a proposal to move marijuana from Schedule I to Schedule III of the Controlled Substances Act (CSA), which President Donald Trump in December directed the attorney general to quickly finalize. That hasn’t happened yet, but if it does, one effect would be allowing state-licensed cannabis businesses to take federal tax deductions under Internal Revenue Service (IRS) code 280E. The CLIMB Act, meanwhile, did not advance in its prior form after being filed in 2022. It remains to be seen whether there will be sufficient bipartisan interest in moving it this session. Some advocates have previously voiced concerns about the idea of advancing reform that heavily favors industry players while marijuana remains federally prohibited and people are still experiencing the collateral consequences of criminalization that the bipartisan bill doesn’t attempt to directly address. Meanwhile, another bipartisan bill that was recently filed in the House by Reps. Maxwell Alejandro Frost (D-FL) and Ryan Mackenzie (R-PA) would repeal a decades-old federal statute that’s led to the denial of housing for millions of people with prior drug convictions. Read the text of the CLIMB Act below: The post Marijuana Businesses Could List On US Stock Exchanges Like Nasdaq And NYSE Under New Bipartisan Congressional Bill appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Alcohol and tobacco cause far more harms to people who consume them, and to society overall, than marijuana does, according to a new government-funded study. A panel of 20 experts with professional experience with substance use issues from across Canada were asked to evaluate 16 different drugs on 10 dimensions of harm to consumers, as well as six dimensions of harm to others, scoring each on a scale of 0 to 100. “Alcohol causes the most harm overall, with a cumulative weighted score of 79,” the study, published in the Journal of Psychopharmacology, found. “It was followed by tobacco (45), nonprescription opioids (33), cocaine (19), methamphetamine (19), and cannabis (15).” The analysis, which was supported with Canadian Institutes for Health Research grant funds, concluded that marijuana’s biggest harm comes not from its effect on consumers but instead is related to the illegal market. “Cannabis’s highest weighted score was for organized criminal activity,” the paper, authored by a large team of academics affiliated with various research institutions throughout Canada, the United Kingdom and New Zealand, says. “Though more than 70 percent of Canadians who purchase cannabis now do so through legal sources, organized criminal groups are heavily involved in the remaining illegal cannabis market, from production to distribution.” Marijuana—which was legalized nationally in Canada in 2018 but remains federally prohibited in the U.S.—is not completely without harms to consumers, however, with the study finding that it “also scored relatively high for mental harms to users (dependence, withdrawal, short- and long-term impairment of mental functioning), ranking third in that combined category.” When it comes to alcohol, which is federally legal in the U.S., it “ranked first in 9 of the 16 harm categories: drug-related damage to physical health, withdrawal, short-term impairment of mental functioning, long-term impairment of mental functioning, loss of tangibles, loss of relationships, injury, family and social adversity, and economic cost,” the study found. “This analysis of drug harms in Canada found that alcohol causes the most harm overall… Alcohol was followed by tobacco, nonprescription opioids (like fentanyl), cocaine, methamphetamine, and cannabis.” Tobacco “ranked first in 4 of the 16 harm categories: drug-related mortality, drug-specific damage to physical health, dependence, and environmental damage,” the researchers wrote. The paper concludes by urging governments to “consider the harm—both individual and societal—caused by drugs and by the laws and regulations that govern them” when developing drug policies. The findings about relative harms of different substances may help explain why alcohol consumption—and particularly tobacco use—have been gradually declining over recent years, and why multiple surveys and studies have indicated that more adults are opting for marijuana. For example, recent polling shows that younger Americans are increasingly using cannabis-infused beverages as a substitute for alcohol—with one in three millennials and Gen Z workers choosing THC drinks over booze for after-work activities like happy hours. Another survey released last October found that a majority of Americans believe marijuana represents a “healthier option” than alcohol. And most also expect cannabis to be legal in all 50 states within the next five years. Smoking marijuana is also associated with “significantly” reduced rates of alcohol consumption, according to a recent federally funded study that involved adults smoking joints in a makeshift bar. A study published in 2024 that looked at adults who drink cannabis-infused beverages found more evidence of a “substitution effect,” with a significant majority of participants reporting reduced alcohol use after incorporating cannabinoid drinks into their routines. In September, an international study identified a a “strong negative association” between tobacco use and legal medical marijuana sales, indicating a “strong potential substitution effect” where people choose to use cannabis where it is allowed instead of smoking cigarettes. Meanwhile, as the Trump administration considers moving marijuana out of Schedule I, the most restrictive category under U.S. federal law, another recent study concluded that cannabis isn’t as dangerous as its current classification would suggest. The post Alcohol And Tobacco Are More Damaging To Users And Society Than Marijuana Is, Government-Funded Study Concludes appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

The demand for Delhi Russian Escorts is growing because of their reputed professionalism and charm. I noticed that communication is always polite and transparent, which builds trust quickly. Services are well-structured and focus on customer comfort. It’s a good choice for those who appreciate a premium and respectful environment while spending quality time with someone who understands refined companionship.

Hire the WhatsApp numbers of newly married and sexy Bhabhis and enjoy sensual pleasure and fun. Bhabhi escorts are a renowned and trusted service, as they are highly experienced and mature females who can easily understand a man's desires and feelings. To experience sensual pleasure with newly married call girls in Jaipur, book our escort service and turn your dreams into reality. This is a premium destination where our agency offers you all kinds of pleasure and satisfaction. Bhabhi escorts know how to give their clients 100% satisfaction. So why wait to meet these young and sexy Bhabhi call girls? You can also find the WhatsApp numbers of real Bhabhi escorts on our site. jaipur call girls || call girls in Jaipur || Jaipur escorts || jaipur escort service || call girls services in Jaipur || Jaipur call girls service || independent call girls in Jaipur || Russian escorts in Jaipur || African Escorts in Jaipur || independent call girl jaipur || vip escort in jaipur || escort service in jaipur || hotel escorts service in jaipur || escorts service in hotel jaipur || low rate call girls in jaipur || Independent Escorts Jaipur || jaipur independent escorts